hat
Akòz kapasite yo yo dwe absòbe rapidman pa kò a, medyòm-chèn trigliserid yo te jwenn itilize nan tretman an nan yon varyete de malabsorption maladi. Gen sipleman MCT ak yon rejim alimantè ki ba anpil grès ki te dekri kòm poto a nan tretman pou maladi Waldmann. MCTs se yon engredyan nan kèk emulsyon espesyalize parantel nitrisyonèl nan kèk peyi. Etid yo te montre tou rezilta pwomèt pou epilepsi nan itilize nan rejim ketojèn. Chwazi syans yo te montre rezilta pwomèt pou maladi neurodegenerativ (egzanp maladi alzayme a ak maladi Parkinson la) men efikasite nan klinik pa poko etabli.
eng
Due to their ability to be absorbed rapidly by the body, medium-chain triglycerides have found use in the treatment of a variety of malabsorption ailments. MCT supplementation with a low-fat diet has been described as the cornerstone of treatment for Waldmann disease. MCTs are an ingredient in some specialized parenteral nutritional emulsions in some countries. Studies have also shown promising results for epilepsy through the use of ketogenic dieting. Select studies have shown promising results for neurodegenerative disorders (e.g. Alzheimer's and Parkinson's diseases) but clinical effectiveness is not yet established.